Chief Scientific Officer and Co-Founder
Godfrey provides scientific leadership to the company through his role as CSO and Director. Godfrey co-founded the company in 2012 and has been responsible for its scientific development since that time. Godfrey is Professor of Cardiac Physiology with a research track record in cardiac electrophysiology.
Head of Software and Modeling & Co-Founder
Francis designed and developed the software behind CellOPTIQ. In addition to his work for Clyde, Francis is a lecturer in cardiovascular physiology at the University of Glasgow. His primary research interest is in discovering the mechanisms of arrhythmias in healthy and diseased hearts by imaging dynamic cellular processes with millisecond resolution at tissue and whole-organ levels. He has an active role in developing and advising on advanced imaging systems and associated software for the company.
Chief Executive Officer
Richard is an experienced CEO, CFO and venture capital partner, with a background in operational roles in industry. He is a Chartered Accountant with a BCom Hons from the University of Edinburgh.
T: +44 (0) 7717 878188
Head of Business Development
Dr Mark Bryant is a consultant specialising in bringing novel human based technologies to the Safety Pharmacology market. In 2001 he developed and launched the first high throughput hERG screening assay using rubidium flux and atomic absorption. In 2009 he developed and launched the first hiPS cardiomyocytes whilst working for ReproCELL. He is currently working with Clyde Biosciences helping to develop and launch their CellOPTIQ platform, which has become one of the leading CIPA assays, using hiPS cardiomyocytes and voltage sensitive dyes.
T: +44 (0) 7801 816212
An experienced biotech executive, Chris brings experience from the pharmaceutical industry to Clyde’s executive team. His background includes commercial roles in pharmaceutical companies of all sizes, as well as senior management experience in one of the world’s leading contract research organisations.